You are here

Generic Version of Glucophage Approved by FDA

PITTSBURGH, Sept. 14 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Metformin Hydrochloride Extended-release Tablets, 500 mg and 750 mg. Metformin HCl ER Tablets, which are the generic version of Bristol-Myers Squibb's Glucophage(R) XR Tablets, 500 mg and 750 mg, had U.S. sales of approximately $173 million, for the 12-month period ending June 30, 2005, according to IMS.

This product will be available soon.

Source: Mylan Laboratories Inc.

Recent Headlines

Findings from ISCHEMIA trial may mean fewer stents and bypass operations for those with stable disease
Donors hope to vaccinate 450 million children each year
New Novartis drug cuts rate of crises by 45% relative to placebo
FDA says new Pentax design is easier to clean
Myovant’s drug would offer a new oral, once-daily treatment option
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention